Role of p53 alteration in primary peritoneal carcinoma

International Journal of Gynecological Pathology

Volumn 16, Issue 2, 1997, Pages 156-162

  Moll, Ute M ^a,c   Valea, Fidel ^b   Chumas, John ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

p53; Primary peritoneal carcinoma; Serous papillary carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; ENDOMETRIOID CARCINOMA; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MIXED MULLERIAN TUMOR; PAPILLARY CARCINOMA; PATHOGENESIS; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030943576     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199704000-00012     Document Type: Article

References (43)

1. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary: case report. Am J Obstet Gynecol 1959;77:197-200.
2. Lauchlan S. The secondary Müllerian system. Obstet Gynecol Surv 1972;27:133-45.
3. Pickartz H. Differential diagnosis of peritoneal lesions of müllerian type and similar epithelial tumors of the peritoneum. Int J Gynecol Pathol 1993;12:116-9.
4. Hernandez E, Atkinson BF, eds. Clinical gynecological pathology. Philadelphia: WB Saunders, 1996.
5. Clark JE, Wood H, Jaffurs WJ, Fabro S. Endometrioid-type cystadenocarcinoma arising in the mesosalpinx. Obstet Gynecol 1979;54:656-8.
6. Banerjee R, Gough F. Cystic mucinous tumors of the mesentery and retroperitoneum: report of three cases. Histopathology 1988;12:527-32.
7. Lee KR, Verma U, Belinson J. Primary clear cell carcinoma of the peritoneum. Gynecol Oncol 1991;41:259-62.
8. Hampton HL, Huffman HT, Meeks GR. Extraovarian Brenner tumors. Obstet Gynecol 1992;79:844-6.
9. Mirc JL, Fenoglio-Preiser CM, Husseinzadeh N. Malignant mixed müllerian tumor of extraovarian secondary müllerian system: report of two cases and review of the English literature. Arch Pathol Lab Med 1995;119:1044-9.
10. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
11. King SA, Adas AA, LiVolsi VA, et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 1995;75:2700-5.
12. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors. Hum Pathol 1995;26:1268-74.
13. Bosari A, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-9.
14. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
15. Klemi P-J, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
16. White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma of the ovary: a clinical, pathologic, ultrastructural and immunohistochemical study of 11 cases. Pathol Annu 1985;20(1):403-18.
17. Rothacker D, Möhius G. Varieties of serous surface papillary carcinoma of the peritoneum in Northern Germany: a thirty year autopsy study. Int J Gynecol Pathol 1995;14:310-8.
18. Gooneratne S, Sassone M, Blaustein A, Talerman A. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982;1:258-69.
19. Mills SE, Andersen WA, Fechner RE, Austin MB. Serous surface papillary carcinoma: a clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol 1988;12:827-34.
20. Truong LD, Maccato ML, Awalt H, Cagle PT, Schwartz MR, Kaplan AL. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 1990;21: 99-110.
21. Ransom D, Patel S, Keeny G, Malhasian G, Edmonson J. Papillary serous carcinoma of the peritoneum: review of 33 cases treated with platin-based chemotherapy. Cancer 1990; 66:1091-4.
22. Gilks CB, Bell DA, Scully RE. Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990;9:110-21.
23. Fromm G-L, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:75-89.
24. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. Cancer 1989;64:110-5.
25. Altaras MM, Aviram R, Cohen I, Cordoba M, Weiss E, Beyth Y. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 1991;4:230-6.
26. Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol 1988;31:315-20.
27. Petru E, Heyderfadai M, Pickel H, Lahousen M, Tamussino K. Primäres seröses Karzinom des Peritoneums: ein Erfahrungsbericht. Geburtshilfe Frauenheilkd 1992;52:533-5.
28. Gitsch G, Tabery U, Feigl W, Breitenecker G. The differential diagnosis of primary peritoneal papillary tumors. Arch Gynecol Obstet 1992;251:139-44.
29. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977;8:83-94.
30. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. Cancer 1995;76:429-36.
31. Saleh WA, Van de Ven C, Kim W. Primary papillary serous carcinoma of the peritoneum: a case of complete remission of bulky peritoneal disease after chemotherapy. Henry Ford Hosp Med J 1992;40:136-8.
32. Bloss JD, Liao S-Y, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51.
33. Raju U, Fine G, Greenwald KA, Ohorodnik JM. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of 8 cases. Hum Pathol 1989;20:426-36.
34. Mulhollan TJ, Silva EG, Tornos C, Guerrieri C, Fromm G-L, Gershenson D. Ovarian involvement by serous surface papillary carcinoma. Int J Gynecol Pathoi 1994;13:120-6.
35. Kohler MF, Kerns J, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81: 643-50.
36. Kupryjanczyk J, Thor AD, Beauchamp R, et al. P53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
37. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
38. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992;11:5013-20.
39. Moll UM, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53-driven pathology. Hum Pathol 1996;27:1295-300.
40. August C, Murad T, Newton M. Multiple focal extraovarian serous carcinoma. Int J Gynecol Pathol 1985;4:11-23.
41. Muto MG, Welch WR, Chi-Ho Mok S, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995;55:490-2.
42. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
43. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma: a morphologically distinctive neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.